Clinical trials: FLU
Influenza
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
- Trial name
- NCT00390884
- Testing
- Influenza Virus Vaccine, Fluzone®
- Where
- 5 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in…
- Trial name
- NCT05446740
- Testing
- GSK4382276A Dose level 1, GSK4382276A Dose level 2, GSK4382276A Dose level 3
- Where
- 7 sites in Belgium, Canada and 1 more
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting…
- Trial name
- CAPSTONE 2 (NCT02949011)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 2,184 people
- Sponsor
- Shionogi
Influenza
Phase 3 Trial of Serbian Seasonal Influenza Vaccine
A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent, split, inactivated influenza vaccine produced by InstituteTorlak.
- Trial name
- Torlak-300 (NCT02935192)
- Testing
- Vaccine
- Where
- 6 sites in Serbia
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Institute of Virology, Vaccines and Sera, Torlak
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza Infection
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular injection of TAK-850 in healthy pediatric Japanese participants.
- Trial name
- NCT02367885
- Testing
- TAK-850 0.5 mL injection, TAK-850 0.25 mL injection
- Where
- 2 sites in Japan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza, Healthy
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.
- Trial name
- FluMist (NCT03158038)
- Testing
- Monovalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic, Avian Influenza
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 influenza season in the Southern Hemisphere.
- Trial name
- NCT00481065
- Testing
- MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a
- Where
- Colombia
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Healthy
Improving Communication During a Pandemic Flu Outbreak
During the last pandemic influenza antivirals were prescribed both as prophylaxis and treatment. However, adherence rates were suboptimal.
- Trial name
- NCT03431012
- Testing
- Agency Assignment framing, Attribute framing
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- King's College London
Diphtheria, Tetanus
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRP~T combined vaccine with Tritanrix-HepB/Hib™, when both are given concomitantly with OPV at 6, 10, and 14 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00348881
- Testing
- DTaP-HB-PRP~T combined vaccine, Tritanrix-HepB/Hib™ vaccine, Oral poliomyelitis vaccine (OPV)
- Where
- 4 sites in Philippines
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza
This open-label study will assess the pharmacokinetics and safety of oseltamivir [Tamiflu] in 3 cohorts of infants, aged 0-30 days, 31-90 days and 91-<365 days with influenza infection.
- Trial name
- NCT01053663
- Testing
- Tamiflu
- Where
- 39 sites in United States, Israel
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Influenza
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
The purpose of this study is to demonstrate the efficacy of an investigational Vero cell-derived, trivalent, seasonal influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the…
- Trial name
- NCT00800605
- Testing
- Vero cell-derived, trivalent, seasonal influenza vaccine
- Where
- 36 sites in United States
- Volunteers
- 7,250 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults
The study is aim to evaluate the safety and immunogenicity of one dose (15 μg HA per strain per dose) of the GPO seasonal trivalent inactivated split virion influenza vaccine (Tri Fluvac) in healthy adults aged 18 to 49 years…
- Trial name
- NCT02894840
- Testing
- an inactivated influenza vaccine
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Influenza Type A, Influenza Type B
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc.
- Conditions
- Influenza Type A, Influenza Type B, Influenza
- Trial name
- NCT04471038
- Testing
- SAB-176, Normal Saline
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza, Otitis Media
Evaluation of Moderate to Severe Influenza Outcomes in Children
The purpose of this study was to determine whether moderate-severe endpoints (including high fever, lower respiratory tract disease, acute otitis media, or serious extra-pulmonary complications) were predictive of…
- Conditions
- Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection
- Trial name
- M2SFlu (NCT02979626)
- Testing
- Respiratory nasal swab
- Where
- 2 sites in United States
- Volunteers
- 1,478 people
- Sponsor
- University of Colorado, Denver
Influenza
Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
This observer blind study is designed to compare the immune response of GSK Biologicals' influenza vaccine GSK576389A when administered using various presentations in adults aged 65 years and older.
- Trial name
- NCT00532298
- Testing
- GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season], GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season], Fluarix [NH 2006/07 season]
- Where
- 6 sites in Denmark, Estonia and 1 more
- Volunteers
- 1,596 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' FluarixTM vaccine in children who have previously been vaccinated with one dose of PandemrixTM at the age…
- Trial name
- NCT01190215
- Testing
- FluarixTM, HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)
- Where
- Finland
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline